GSK’s Patrick Vallance on a new generation antibiotics


GSK’s President of Pharmaceutical R&D explains why GSK is involved in challenging antibiotics resistance.

Related tags

Explore more features

Bio electronics human

Innovation

Biolectronic medicines: Harnessing body's electrical language

Andrew Witty - Davos interview

How we do business

Bloomberg TV: Sir Andrew Witty, CEO, GSK, discusses antibiotic resistance in Davos

Andrew Witty, Chief Executive Officer, GSK, discusses antibiotic effectiveness, the issues surrounding drug pricing and corporate inversions. He speaks to Bloomberg's Jonathan Ferro and Hans Nichols on "Countdown" from the World Economic Forum in Davos, Switzerland, January 2016.

Bioelectronic pathways

Behind the science

Leading future science | GSK medical science

Our challenge was to accelerate 10 years to 10 months, fast tracking our research and development.

Back to top